IngenOx Therapeutics develops precision cancer vaccines targeting late-stage solid tumors and relapsed or refractory lymphomas, addressing the urgent need for effective treatments in patients with poor prognoses. The company utilizes a proprietary platform to generate novel therapeutic candidates backed by robust scientific and clinical data, advancing them through clinical development towards marketing approval.
Funding
Funding not disclosed
Founders
Product
Problem
Many late-stage solid tumors and relapsed or refractory lymphomas are resistant to existing treatments, resulting in poor prognoses for affected patients. These cancers often evade immune detection, limiting the effectiveness of current immunotherapies.
Solution
IngenOx Therapeutics is developing precision cancer vaccines and drugs designed to treat advanced cancers that are resistant to chemotherapy and current immunotherapies. The company's approach focuses on revealing hidden cancers and enabling the immune system to recognize and destroy them. IngenOx utilizes a proprietary platform to generate novel therapeutic candidates, including cancer vaccines tailored to distinct tumor types and small molecule inhibitors. These assets are designed to target immunologically cold tumors, offering safer, more effective treatments for patients with limited viable options. The company is advancing a multi-asset pipeline through clinical development, with the goal of bringing targeted therapies to patients facing the greatest need.
Target Audience
The primary target audience includes patients with late-stage solid tumors and relapsed or refractory lymphomas who have limited treatment options, as well as the clinicians who treat them.
Features
- Precision cancer vaccines designed to prevent relapse or spread of colorectal cancer, currently entering Phase 1 clinical studies.
- Zabadinostat (CXD101): A drug with demonstrated clinical activity in lymphoma and microsatellite-stable (MSS) colorectal cancer, with ongoing trials in liver cancer.
- PRMT5 Inhibitor (AT101): A small molecule inhibitor of PRMT5 undergoing IND-enabling studies, paired with a companion diagnostic to identify patients most likely to benefit.
- In-house platform supports both small molecule drug discovery and vaccine development.